Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 5;35(6):278-286.
doi: 10.2188/jea.JE20240284. Epub 2025 Feb 28.

Three-year Seroprevalence of SARS-CoV-2 Nucleocapsid Protein Antibody Among Children, Parental Awareness, and Contributors of Infection: A Single-school Cohort Study in Chiba, Japan

Affiliations

Three-year Seroprevalence of SARS-CoV-2 Nucleocapsid Protein Antibody Among Children, Parental Awareness, and Contributors of Infection: A Single-school Cohort Study in Chiba, Japan

Midori Yamamoto et al. J Epidemiol. .

Abstract

Background: Coronavirus disease 2019 (COVID-19) in children is often asymptomatic, posing challenges in detecting infections. Additionally, factors contributing to infection remain poorly understood. This study aimed to investigate trends in anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid antibody seroprevalence, the relationship between seroprevalence and parental perception of child infection, and factors related to COVID-19 in children.

Methods: In December 2020, 355 children aged 6-12 years in one elementary school were enrolled in the study. The anti-SARS-CoV-2 nucleocapsid antibody seroprevalence was assessed, and questionnaires were administered annually for 3 years. Parents' perceptions of infection and factors contributing to infection were examined.

Results: The seroprevalence was 0.6%, 2.2%, and 60.9% in the first, second, and third years, respectively. The third-year seroprevalence among children reported as 'infected,' 'not tested but had symptoms,' and 'not infected' by parents was 97.3%, 83.3%, and 35.7%, respectively. Increased odds of seropositivity at the third-year measurement were observed in lower grades (adjusted odds ratio [aOR] 2.79 compared with higher grades) and in children more likely to play with others (aOR 3.97 for 'somewhat' and aOR 2.84 for 'often,' compared with 'rarely'). No significant associations with seropositivity were found for sex, siblings, body mass index, serum 25-OH vitamin D3 concentration, or sleep duration.

Conclusion: The Omicron variant outbreak from the end of 2021 led to a sharp increase in seroprevalence among children, with many unaware of their infection. Frequent play with others may facilitate transmission in children. These data provide useful information for developing countermeasures against COVID-19 and other future pandemics.

Keywords: SARS-CoV-2; awareness; child’s infection; contributing factor; seroprevalence.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: None declared.

Figures

Figure 1.
Figure 1.. The data collection timeline in the Study of Child Health and Lifestyle during the coronavirus disease 2019 pandemic
Figure 2.
Figure 2.. Reported cases of SARS-CoV-2 infection (%).
(A) In all of Japan and Chiba Prefecture and (B) in children whose parents responded to the questionnaire in this study. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Similar articles

References

    1. WHO. Origin of SARS-CoV-2. https://iris.who.int/bitstream/handle/10665/332197/WHO-2019-nCoV-FAQ-Vir...; 2020 Accessed 06.03.2024.
    1. Li Q, Guan X, Wu P, et al. . Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–1207. 10.1056/NEJMoa2001316 - DOI - PMC - PubMed
    1. WHO. COVID-19 dashboard. https://data.who.int/dashboards/covid19/cases?n=c; 2024 Accessed 06.03.2024.
    1. COVID-19 Cumulative Infection Collaborators . Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis. Lancet. 2022;399:2351–2380. 10.1016/S0140-6736(22)00484-6 - DOI - PMC - PubMed
    1. Bergeri I, Whelan MG, Ware H, et al. ; Unity Studies Collaborator Group . Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: a systematic review and meta-analysis of standardized population-based studies. PLoS Med. 2022;19:e1004107. 10.1371/journal.pmed.1004107 - DOI - PMC - PubMed

Substances